Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief
Response Includes Contribution to Three New Jersey Area Organizations
BRIDGEWATER, N.J., Nov. 19, 2012
BRIDGEWATER, N.J., Nov. 19, 2012 /PRNewswire/ --Sanofi today announced that,
through its Sanofi Foundation for North America, it is contributing $500,000
in cash, for disaster relief efforts to help assist the victims of Hurricane
Sandy in New Jersey. The funds will be distributed to the Hurricane Sandy New
Jersey Relief Fund, the Community Food Bank of New Jersey and the Children's
Health Fund for both immediate and long-term needs. The storm left millions in
the mid-Atlantic and New England without power, food and other necessities and
may result in $50 billion in economic losses.
"This storm has been a catastrophe that has touched us all. With our U.S.
headquarters in Bridgewater, New Jersey, where much of the damage occurred, we
have seen, first-hand, the devastating impact of Hurricane Sandy on our
employees, friends and neighbors. Our heart goes out to the victims of the
storm," said Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "We
are committed to helping those impacted by the storm and hope that our
assistance will support the incredible relief efforts that are underway in the
hardest hit areas at the point of need."
A special Hurricane Sandy Disaster Relief program sponsored by the Sanofi
Foundation for North America will match dollar-for-dollar all donations
between $25 and $2,500 made by U.S. employees directly to the American Red
Cross. Sanofi US will continue its year-round matching gifts program through
AmeriGives, which will match donations to 501(c)(3) organizations that meet
Additional support from Sanofi to Sandy's disaster relief efforts includes the
donation of medications, over-the-counter products, and vaccines through its
partnership with Direct Relief International and AmeriCares.
Sanofi's employees have offered unwavering assistance to peers and their
communities assisting through direct, hands-on volunteer efforts for
care-package assembly, time and talents offerings, and other donations.
About the Sanofi Foundation for North America
The Sanofi Foundation for North America makes it possible to provide free
prescription drugs to patients who do not have insurance coverage and who meet
program eligibility requirements. Product is donated to the Foundation by the
company for this purpose. The Foundation also provides monetary support and
partners with charities and 501(c)3 organizations and other entities that are
strategically aligned with mission particularly access to health care.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US. For more information on Sanofi US,
please visit http://www.sanofi.us or call 1-800-981-2491.
Sanofi US is also on Twitter and Facebook. Visit us at
https://twitter.com/SanofiUS and http://www.facebook.com/sanofiUS.
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995,as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects","anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Contact: Jack Cox, +1-908-981-5280, Jack.Cox@sanofi.com
Press spacebar to pause and continue. Press esc to stop.